Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| They had a good 2023 of commercial uptake in the United States |
| And we significantly strengthened our balance sheet with a partial monetization of our Ultomiris and Monjuvi royalties |
| We've made great progress and we really hope that this year, we'll have a lot more knowledge about it |
| Well positioned -- we're well positioned to ramp up again, but it's about focus now |
| Because each of these studies that we're looking at are peer studies, are exciting, right? We're excited about Xaluritamig and the clinical response there |
| This is why we're quite encouraged with what we're seeing in the cohort now with clinical activity of vudalimab monotherapy |
| I'm excited about the encouraging new data we have to share from the prostate cancer monotherapy cohort |
| And I think that's given us a good feeling that the Q3 week might have some benefits over the Q2 week weight-based dosing |
| Also, we think renal cell carcinoma has a need for new mechanisms beyond checkpoint inhibitors and TKIs, and directly cytotoxic antibody could be well positioned |
| The emergent signal that we have in a small end right now is better than anything that was achieved in that study in a comparable patient population post-taxane patients |
| Overall, we are encouraged by the tolerability profile of the Q3 week flat dosing schedule with vudalimab |
| So, we're excited for what we're seeing |
| So, we're very encouraged to see this early data for the molecule in the 2+1 format |
| Overall, considering the early nature of the vudalimab monotherapy cohort, we are encouraged by the clinical benefit for these advanced prostate cancer patients that have been treated well beyond current standard of care, and we look forward to evaluating a larger cohort of patients by year-end |
| Our partner, Amgen, presented very promising efficacy and tolerability data at ESMO last October in late-line prostate cancer, usually considered a cold tumor for immunotherapy |
| Reduction in target lesions and disease control are encouraging for such a heavily pretreated patient population, as you can see on the right, with a RECIST response rate of 35% and a disease control rate of 50% and the spider plot shows we have several lasting responses and one patient with stable disease past 48 weeks |
| When you put the data into the context of the broader novel therapeutic landscape under development, it really is clear why we and our investigators during our discussion at ASCO GU were so encouraged about continuing the study |
| We're starting with a strong balance sheet and as you can see, we're looking forward to this year really bringing the focus to our solid tumor bispecifics pipeline, where we have a lot going on for our CD3 and CD28 T-cell engagers and for vudalimab |
| In summary, we have observed encouraging single-agent activity in heavily pretreated patient population |
| And right now, based on some of the durability, seems like we're in pretty good shape |
| Our plug-and-play antibody modules let us do this work rapidly, and as a result, we've got a growing pipeline of molecules with our 2+1 design, which is particularly helpful with selectivity for solid tumors |
| For vudalimab, we initiated a new study, its first front-line study, in non-small cell lung cancer, based both on our Phase 1 data in lung cancer and external data, suggesting potential advantages against standard checkpoint therapy in this setting |
| And so far, based on feedback from investigators, we seem to be seeing better tolerability with these new regimens than the prior one |
| CD28 targeting has generated a lot of interest among clinicians and across the industry in the current Phase 1 study in combination with pembrolizumab is progressing well in escalation |
| And we've made progress with our metastatic castration-resistant prostate cancer studies, both in combination with chemo and monotherapy and with encouraging monotherapy data we're going to present in a moment |
| That said, the survival curves are a bit better for that line in that setting with Docetaxel monotherapy |
| We picked B7-H3 because it offers high expression across a range of tumor types, creating an opportunity to potentially treat multiple cancers in combination with either checkpoint inhibitors or CD3 bispecifics |
| 819's design gives us the selectivity we wanted in vitro and we're continuing to advance in dose escalation with both IV and subcutaneous dosing and expect to make significant progress this year toward target dose levels |
| The focus of our clinical pipeline is bispecific T-cell engagers for solid tumors, an area with rapidly growing promise |
| Now, on the next slide, beyond prostate cancer, we are executing on the start of our frontline non-small cell lung cancer study of vudalimab plus chemotherapy, and we are excited that the study is underway with the first patient dose in the fourth quarter of last year |
| Statement |
|---|
| Solid tumors have been challenging for antibody and cell therapies |
| To describe one especially poor prognostic patient who responded well to vudalimab, this patient had three liver mets, a total disease burden of 12 centimeters and PSA at baseline of 180 nanograms per mil, and achieved a confirmed PR, a PSA90, and was in response for over 22 weeks |
| Comparatively, only the Xaluritamig dose escalation study has enrolled similar patients that are very late-line in poor performance status |
| Though it has a very promising expression profile, it is a selectivity design challenge because there are multiple closely homologous CLDNs |
| This target was challenging due to the limited accessible binding regions outside the cell membrane and non-tumor expression |
| But I think what we could say is a number of these programs, Xaluritamig, I think is undeniable |
| The patient had responded to therapy, but did have other treatment-emergent adverse events before that, including diabetes mellitus and diabetic ketoacidosis, a thyroiditis, a hyperkalemia, lipase increase |
Please consider a small donation if you think this website provides you with relevant information